Summary:
The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly Trulicity when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.
Inclusion Criteria:
- Have type 2 diabetes mellitus (T2DM) for at least 6 months
- Have been treated with stable metformin dose for at least 3 months
- Have HbA1c ≥7.5% and ≤11.0% at study entry
- Have body mass index (BMI) ≥25 kilograms per meter squared (kg/m^2)
Exclusion Criteria:
- Have used any glucagon-like peptide-1 receptor agonist (GLP-1 RA) or insulin, not including prior short term insulin use (≤14 days)
- Have been taking any other medicine for diabetes (other than metformin) during the last 3 months
- Have used in the last 3 months (or plan to use) prescription weight loss medications
- Have disorders associated with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss
- Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine transaminase (ALT) level >2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial
- Had chronic or acute pancreatitis any time prior to study entry
- Have had a heart attack or stroke in the past 2 months, or have heart failure that significantly limits their physical activity
Qualified Participants May Receive:
Patient will receive study-related care and investigational study medication as well as a travel stipend for each completed visit.